Rohrig Abie, Eyal Nir
1Day Sooner, New York, USA.
Department of Philosophy, Swarthmore College, Swarthmore, Pennsylvania, USA.
J Infect Dis. 2022 Mar 15;225(6):934-937. doi: 10.1093/infdis/jiab488.
The world's first coronavirus disease 2019 human challenge trial using the D614G strain of severe acute respiratory syndrome 2 (SARS-CoV-2) is underway in the United Kingdom. The Wellcome Trust is funding challenge stock preparation of the Beta and Delta variant for a follow-up human challenge trial, and researchers at hVIVO are considering conducting these trials. However, little has been written thus far about the ethical justifiability of human challenge trials with SARS-CoV-2 variants of concern. We explore 2 specific characteristics of some variants that may initially be thought to make such trials unethical and conclude that SARS-CoV-2 variant challenge trials can remain ethical.
世界上首个使用严重急性呼吸综合征冠状病毒2（SARS-CoV-2）D614G毒株进行的2019冠状病毒病人体挑战试验正在英国进行。惠康基金会正在资助针对贝塔和德尔塔变种的挑战病毒株制备工作，用于后续的人体挑战试验，hVIVO的研究人员也在考虑开展这些试验。然而，迄今为止，关于针对值得关注的SARS-CoV-2变种进行人体挑战试验的伦理合理性，相关论述甚少。我们探究了一些变种的两个特定特征，这些特征最初可能被认为会使此类试验不符合伦理，并得出结论：SARS-CoV-2变种挑战试验仍可符合伦理。
